BR112012030479A2 - terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1 - Google Patents
terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1Info
- Publication number
- BR112012030479A2 BR112012030479A2 BR112012030479A BR112012030479A BR112012030479A2 BR 112012030479 A2 BR112012030479 A2 BR 112012030479A2 BR 112012030479 A BR112012030479 A BR 112012030479A BR 112012030479 A BR112012030479 A BR 112012030479A BR 112012030479 A2 BR112012030479 A2 BR 112012030479A2
- Authority
- BR
- Brazil
- Prior art keywords
- cyclin
- associated antigens
- cancer therapy
- therapy based
- derived tumor
- Prior art date
Links
- 108050006400 Cyclin Proteins 0.000 title abstract 3
- 102000016736 Cyclin Human genes 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 238000011275 oncology therapy Methods 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1. a presente invenção refere-se a peptídeos derivados de ciclina para o uso no tratamento aprimorado do câncer em um paciente, particularmente na forma de uma combinação de terapia usando uma vacina. outros aspectos se relacionam com o uso dos peptídeos ou de uma combinação deles como um ferramenta diagnóstica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35073110P | 2010-06-02 | 2010-06-02 | |
GB201009222A GB201009222D0 (en) | 2010-06-02 | 2010-06-02 | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
PCT/EP2011/059121 WO2011151403A1 (en) | 2010-06-02 | 2011-06-01 | Improved cancer therapy based on tumor associated antigens derived from cyclin d1 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012030479A2 true BR112012030479A2 (pt) | 2017-01-24 |
Family
ID=42471037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012030479A BR112012030479A2 (pt) | 2010-06-02 | 2011-06-01 | terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1 |
Country Status (16)
Country | Link |
---|---|
US (2) | US9023803B2 (pt) |
EP (1) | EP2575850A1 (pt) |
JP (1) | JP2013536157A (pt) |
KR (1) | KR20130089175A (pt) |
CN (1) | CN102971003A (pt) |
AU (1) | AU2011260277B2 (pt) |
BR (1) | BR112012030479A2 (pt) |
CA (1) | CA2793601A1 (pt) |
EA (1) | EA201291195A1 (pt) |
GB (1) | GB201009222D0 (pt) |
MX (1) | MX2012013998A (pt) |
MY (1) | MY162741A (pt) |
NZ (1) | NZ601677A (pt) |
SG (1) | SG185353A1 (pt) |
UA (1) | UA110473C2 (pt) |
WO (1) | WO2011151403A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
CN103848891B (zh) * | 2012-11-30 | 2015-09-09 | 北京市结核病胸部肿瘤研究所 | Ccnd1自身抗体识别的抗原多肽 |
CA2840988A1 (en) * | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Wt1 peptide cancer vaccine composition for mucosal administration |
IN2014CH00391A (pt) * | 2013-02-05 | 2015-04-03 | Nitto Denko Corp | |
IL300761A (en) | 2013-08-05 | 2023-04-01 | Immatics Biotechnologies Gmbh | Innovative immunotherapy against several tumors, such as lung cancer, including NSCLC |
TWI777197B (zh) * | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(六) |
CN104017051B (zh) * | 2014-06-23 | 2016-08-17 | 深圳市华中生物药械有限公司 | 一种Cyclin D 蛋白抑制剂多肽及其应用 |
GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
CN107864654B (zh) | 2015-06-19 | 2022-03-15 | 伊玛提克斯生物技术有限公司 | 用于免疫治疗的新型肽和肽组合物以及用于胰腺癌和其他癌症的支架产生方法 |
GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
ZA201707555B (en) | 2015-06-25 | 2018-11-28 | Immatics Biotechnologies Gmbh | Novel cell epitopes and combination of cell epitopes for use in the immuno-therapy of myeloma and other cancers |
IL308735A (en) | 2015-07-01 | 2024-01-01 | Immatics Biotechnologies Gmbh | New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer |
GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
MX2017017148A (es) | 2015-07-06 | 2018-02-23 | Immatics Biotechnologies Gmbh | Peptidos novedosos y combinacion de peptidos para usarse en la inmunoterapia contra cancer esofagico y otros canceres. |
GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
MY198087A (en) | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
MA55153A (fr) | 2016-02-19 | 2021-09-29 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers |
GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
MA54832A (fr) * | 2016-03-01 | 2021-12-01 | Immatics Biotechnologies Gmbh | Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers |
GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
CN112553336B (zh) * | 2020-12-17 | 2023-07-21 | 兰州大学 | Snp在乳腺癌化疗耐药性检测领域的应用及其检测试剂盒 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
DE10225144A1 (de) * | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
WO2005035714A2 (en) | 2003-08-26 | 2005-04-21 | Board Of Regents, The University Of Texas System | Vaccines for cancer, autoimmune disease and infections |
DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
EP1642905B1 (en) | 2004-10-02 | 2009-01-21 | Immatics Biotechnologies GmbH | Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes |
ATE440107T1 (de) * | 2005-09-05 | 2009-09-15 | Immatics Biotechnologies Gmbh | Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe |
PT1806358E (pt) | 2005-09-05 | 2010-05-28 | Immatics Biotechnologies Gmbh | Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii |
US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
WO2009015841A1 (en) | 2007-07-27 | 2009-02-05 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
WO2009059011A2 (en) * | 2007-11-01 | 2009-05-07 | Mayo Foundation For Medical Education And Research | Hla-dr binding peptides and their uses |
DK2119726T5 (en) * | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
AU2010222930B2 (en) * | 2008-07-16 | 2013-07-25 | Baylor Research Institute | Antigen presenting cell targeted cancer vaccines |
GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
-
2010
- 2010-06-02 GB GB201009222A patent/GB201009222D0/en not_active Ceased
-
2011
- 2011-06-01 SG SG2012065918A patent/SG185353A1/en unknown
- 2011-06-01 UA UAA201210089A patent/UA110473C2/uk unknown
- 2011-06-01 WO PCT/EP2011/059121 patent/WO2011151403A1/en active Application Filing
- 2011-06-01 MX MX2012013998A patent/MX2012013998A/es active IP Right Grant
- 2011-06-01 CA CA2793601A patent/CA2793601A1/en not_active Abandoned
- 2011-06-01 EA EA201291195A patent/EA201291195A1/ru unknown
- 2011-06-01 KR KR1020127034291A patent/KR20130089175A/ko not_active Application Discontinuation
- 2011-06-01 BR BR112012030479A patent/BR112012030479A2/pt not_active IP Right Cessation
- 2011-06-01 JP JP2013512926A patent/JP2013536157A/ja active Pending
- 2011-06-01 US US13/643,043 patent/US9023803B2/en active Active
- 2011-06-01 AU AU2011260277A patent/AU2011260277B2/en not_active Ceased
- 2011-06-01 MY MYPI2012700611A patent/MY162741A/en unknown
- 2011-06-01 EP EP11722825.4A patent/EP2575850A1/en not_active Withdrawn
- 2011-06-01 NZ NZ60167711A patent/NZ601677A/en not_active IP Right Cessation
- 2011-06-01 US US13/150,785 patent/US9056069B2/en active Active
- 2011-06-01 CN CN2011800266565A patent/CN102971003A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2012013998A (es) | 2013-01-28 |
MY162741A (en) | 2017-07-15 |
US9023803B2 (en) | 2015-05-05 |
AU2011260277B2 (en) | 2015-01-15 |
EP2575850A1 (en) | 2013-04-10 |
EA201291195A1 (ru) | 2014-06-30 |
US9056069B2 (en) | 2015-06-16 |
CA2793601A1 (en) | 2011-12-08 |
GB201009222D0 (en) | 2010-07-21 |
CN102971003A (zh) | 2013-03-13 |
JP2013536157A (ja) | 2013-09-19 |
UA110473C2 (uk) | 2016-01-12 |
WO2011151403A1 (en) | 2011-12-08 |
AU2011260277A1 (en) | 2012-08-30 |
NZ601677A (en) | 2015-01-30 |
SG185353A1 (en) | 2012-12-28 |
US20130177525A1 (en) | 2013-07-11 |
US20120027684A1 (en) | 2012-02-02 |
KR20130089175A (ko) | 2013-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012030479A2 (pt) | terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1 | |
HK1247567A1 (zh) | 用於治療癌症的涉及針對密蛋白18.2之抗體的聯合治療 | |
BR112015010740A2 (pt) | Agentes para tratamento de doenças cancerosas expressando claudina | |
GT201700033A (es) | Anticuerpos anti tigit | |
MX2021008224A (es) | Combinacion de vacunacion e inhibicion de la trayectoria pd-1. | |
PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
CL2015000431A1 (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis. | |
MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
HK1208152A1 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer 182 | |
EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
CR20190140A (es) | Anticuerpos anti-cd27 | |
TWD161529S (zh) | 治療燈 | |
MX346555B (es) | Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1). | |
CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
BR112017025533A2 (pt) | método para tratar câncer em um paciente humano | |
CO6741197A2 (es) | Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma | |
TR201910413T4 (tr) | Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler. | |
BR112017011777A2 (pt) | antagonista de a2a de dosagem baixa para o tratamento de tdah e doença de parkinson | |
MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
BR112014031556A2 (pt) | derivados de bendamustina e compostos relacionados, e uso médico dos mesmos na terapia do câncer | |
MX2013003859A (es) | Polimorfos de picropodofilina b o c para su uso en la terapia del cancer. | |
IN2013MU03118A (pt) | ||
EP2879705A4 (en) | PEPTIDE VACCINES BASED ON THE EGFRVIII SEQUENCE FOR THE TREATMENT OF TUMORS | |
CY1118255T1 (el) | Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |